Method for inhibiting telomerase in cancer cell using luterion
US10406188B1 · kind B1 · utility
0Cited by
9References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 5, 2017 |
| Grant date | Sep 10, 2019 |
| Priority date | — |
| Expiry date | Jul 5, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a method for inhibiting telomerase in cancer cells by means of luterion and, more particularly, to a method for inhibiting telomerase activity in cancer tissues, cancer cells or a cancer patient, the method in which administered are: an anti-cancer composition comprising luterion; a composition for inhibiting telomerase activity in cancer cells; and luterion. Luterion, according to the present disclosure, has the advantage of effectively inhibiting only the proliferation of cancer cells, without affecting normal cells, by inhibiting telomerase activity in cancer cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.